non-cystic fibrosis bronchiectasis - Search News

News

FDA, bronchiectasis and Cystic Fibrosis

Medical Dialogues · 13h

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a first-in-class reversible DPP-1 inhibitor, it targets the

UPI on MSN · 2d

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

Clinical Advisor · 1d

Brinsupri Approved for Non-Cystic Fibrosis Bronchiectasis

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Stocktwits on MSN2d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Pharmaceutical Technology3d

Fosun and Expedition make $645m licensing deal for respiratory drug

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results